Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE40.5000
- TODAY'S CHANGE (%)0.4000 (0.9975%)
- Bid / Lots35.0000/ 1
- Ask / Lots65.0500/ 2
- Open / Previous Close40.0200 / 40.1000
- Day Range
- 52 Week Range
- Volume320,772
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1133 | 40.43 |
| 09:36 ET | 100 | 39.8 |
| 09:39 ET | 100 | 40.135 |
| 09:41 ET | 5196 | 40.56 |
| 09:43 ET | 174 | 40.34 |
| 09:48 ET | 500 | 40.335 |
| 09:50 ET | 300 | 40.35 |
| 09:56 ET | 100 | 40.23 |
| 09:57 ET | 108 | 40.1553 |
| 09:59 ET | 1095 | 40.355 |
| 10:01 ET | 300 | 40.46 |
| 10:03 ET | 300 | 40.44 |
| 10:06 ET | 100 | 40.41 |
| 10:08 ET | 900 | 40.5 |
| 10:10 ET | 100 | 40.51 |
| 10:17 ET | 300 | 40.42 |
| 10:19 ET | 13902 | 40.355 |
| 10:21 ET | 2859 | 40.54 |
| 10:24 ET | 100 | 40.45 |
| 10:28 ET | 100 | 40.435 |
| 10:30 ET | 1800 | 40.5 |
| 10:32 ET | 3436 | 40.5 |
| 10:35 ET | 6955 | 40.5 |
| 10:37 ET | 100 | 40.53 |
| 10:42 ET | 400 | 40.58 |
| 10:44 ET | 200 | 40.47 |
| 10:46 ET | 2101 | 40.57 |
| 10:48 ET | 200 | 40.5 |
| 10:50 ET | 400 | 40.58 |
| 10:51 ET | 109 | 40.585 |
| 10:53 ET | 300 | 40.63 |
| 10:55 ET | 1800 | 40.62 |
| 10:57 ET | 100 | 40.62 |
| 11:00 ET | 300 | 40.615 |
| 11:02 ET | 100 | 40.615 |
| 11:04 ET | 400 | 40.62 |
| 11:06 ET | 200 | 40.63 |
| 11:08 ET | 3634 | 40.72 |
| 11:09 ET | 600 | 40.6825 |
| 11:11 ET | 1189 | 40.62 |
| 11:15 ET | 100 | 40.6 |
| 11:24 ET | 400 | 40.595 |
| 11:31 ET | 321 | 40.6 |
| 11:33 ET | 100 | 40.62 |
| 11:36 ET | 200 | 40.545 |
| 11:38 ET | 100 | 40.565 |
| 11:40 ET | 100 | 40.575 |
| 11:42 ET | 12240 | 40.635 |
| 11:44 ET | 400 | 40.52 |
| 11:45 ET | 406 | 40.59 |
| 11:47 ET | 100 | 40.56 |
| 11:54 ET | 400 | 40.62 |
| 11:56 ET | 100 | 40.635 |
| 11:58 ET | 400 | 40.7 |
| 12:00 ET | 1800 | 40.64 |
| 12:02 ET | 100 | 40.69 |
| 12:03 ET | 400 | 40.63 |
| 12:05 ET | 100 | 40.675 |
| 12:09 ET | 100 | 40.67 |
| 12:12 ET | 100 | 40.72 |
| 12:14 ET | 100 | 40.69 |
| 12:16 ET | 1400 | 40.635 |
| 12:20 ET | 1400 | 40.7 |
| 12:21 ET | 900 | 40.72 |
| 12:27 ET | 200 | 40.66 |
| 12:30 ET | 300 | 40.72 |
| 12:32 ET | 200 | 40.65 |
| 12:34 ET | 500 | 40.7 |
| 12:38 ET | 400 | 40.67 |
| 12:39 ET | 1708 | 40.67 |
| 12:41 ET | 100 | 40.66 |
| 12:43 ET | 802 | 40.65 |
| 12:45 ET | 100 | 40.655 |
| 12:50 ET | 100 | 40.65 |
| 12:54 ET | 300 | 40.65 |
| 12:59 ET | 800 | 40.71 |
| 01:01 ET | 200 | 40.7 |
| 01:06 ET | 100 | 40.7 |
| 01:08 ET | 100 | 40.675 |
| 01:10 ET | 600 | 40.665 |
| 01:15 ET | 200 | 40.675 |
| 01:17 ET | 600 | 40.71 |
| 01:19 ET | 500 | 40.67 |
| 01:24 ET | 800 | 40.69 |
| 01:26 ET | 200 | 40.67 |
| 01:28 ET | 100 | 40.66 |
| 01:30 ET | 500 | 40.58 |
| 01:32 ET | 100 | 40.58 |
| 01:33 ET | 100 | 40.56 |
| 01:35 ET | 201 | 40.59 |
| 01:42 ET | 300 | 40.62 |
| 01:44 ET | 100 | 40.59 |
| 01:46 ET | 700 | 40.63 |
| 01:48 ET | 1230 | 40.645 |
| 01:50 ET | 500 | 40.71 |
| 01:51 ET | 1300 | 40.655 |
| 01:53 ET | 300 | 40.69 |
| 01:55 ET | 1200 | 40.68 |
| 02:00 ET | 1200 | 40.685 |
| 02:02 ET | 2100 | 40.69 |
| 02:04 ET | 400 | 40.67 |
| 02:06 ET | 3756 | 40.67 |
| 02:08 ET | 500 | 40.645 |
| 02:13 ET | 500 | 40.56 |
| 02:20 ET | 6608 | 40.54 |
| 02:22 ET | 371 | 40.51 |
| 02:24 ET | 12296 | 40.54 |
| 02:26 ET | 2690 | 40.47 |
| 02:27 ET | 536 | 40.45 |
| 02:29 ET | 700 | 40.5 |
| 02:31 ET | 200 | 40.55 |
| 02:40 ET | 700 | 40.59 |
| 02:44 ET | 100 | 40.555 |
| 02:45 ET | 295 | 40.55 |
| 02:47 ET | 1100 | 40.59 |
| 02:49 ET | 300 | 40.54 |
| 02:51 ET | 580 | 40.53 |
| 02:54 ET | 255 | 40.5201 |
| 02:56 ET | 6027 | 40.5 |
| 02:58 ET | 100 | 40.5 |
| 03:00 ET | 2255 | 40.59 |
| 03:03 ET | 800 | 40.5 |
| 03:05 ET | 1172 | 40.5 |
| 03:07 ET | 100 | 40.515 |
| 03:09 ET | 200 | 40.52 |
| 03:14 ET | 100 | 40.52 |
| 03:16 ET | 500 | 40.52 |
| 03:20 ET | 14466 | 40.5 |
| 03:21 ET | 10536 | 40.52 |
| 03:25 ET | 1400 | 40.51 |
| 03:27 ET | 1807 | 40.52 |
| 03:30 ET | 900 | 40.55 |
| 03:32 ET | 1826 | 40.63 |
| 03:34 ET | 100 | 40.63 |
| 03:36 ET | 1600 | 40.67 |
| 03:38 ET | 1636 | 40.67 |
| 03:39 ET | 4990 | 40.65 |
| 03:41 ET | 1200 | 40.69 |
| 03:43 ET | 1600 | 40.67 |
| 03:45 ET | 400 | 40.6 |
| 03:48 ET | 2508 | 40.59 |
| 03:50 ET | 1200 | 40.63 |
| 03:52 ET | 300 | 40.61 |
| 03:54 ET | 4208 | 40.51 |
| 03:56 ET | 20857 | 40.54 |
| 03:57 ET | 4958 | 40.54 |
| 03:59 ET | 6672 | 40.5 |
Apr 16, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 12, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones
7:13AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 10, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
9:57AM ET on Wednesday Apr 10, 2024 by Dow JonesXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 4, 2024
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference, from 4:01PM ET on Thursday Apr 04, 2024 by Dow Jones
4:01PM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.1B | -14.8x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 3.3B | -6.1x | --- |
IDEAYA Biosciences Inc | 3.0B | -20.4x | --- |
Crinetics Pharmaceuticals Inc | 3.3B | -11.4x | --- |
CG Oncology Inc | 2.7B | -38.4x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -14.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
